Immunic (IMUX) Cash & Equivalents (2013 - 2026)

Immunic has reported Cash & Equivalents for 14 years, with the latest figure at $186.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 1204.53% year-over-year to $186.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.6 million (up 1204.53% YoY) and the FY2025 annual result came in at $15.5 million, down 56.59% from the prior year.
• Cash & Equivalents improved to $186.6 million in Q1 2026 per IMUX's latest filing, from $15.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $186.6 million in Q1 2026 and troughed at $14.3 million in Q1 2025.
• A 5-year average of $71.7 million and a median of $72.8 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents tumbled 85.3% in 2025, then soared 1204.53% in 2026.
• Over 5 years, Cash & Equivalents stood at $106.7 million in 2022, then tumbled by 56.28% to $46.7 million in 2023, then declined by 23.58% to $35.7 million in 2024, then plunged by 56.59% to $15.5 million in 2025, then surged by 1105.19% to $186.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $186.6 million, $15.5 million, and $35.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.